NCI-2025-01827

Pilot trial of the IL-4 Receptor Antagonist Dupilumab plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

This research study is testing a new combination of medicines for people with a tough-to-treat type of breast cancer called triple-negative breast cancer (TNBC). It focuses on patients whose cancer is locally advanced, meaning it's large or has spread to nearby lymph nodes, but not to distant parts of the body. Dupilumab is normally used for asthma or eczema, this drug blocks a signal in the immune system (called IL-4) that might help cancer grow or avoid detection. Pembrolizumab is an immunotherapy that helps the body’s immune system attack cancer. Paclitaxel is a chemotherapy drug that slows or stops cancer cell growth. Carboplatin is another chemo drug that damages cancer cells. Together, the goal is to boost the immune response while also using proven chemotherapy.

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

Triple Negative Breast Cancer: It is a type of breast cancecancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06637306

Clinical Trial Site: Sinai

To see all available clinical trials click here.